Key late breaking and recommended sessions we will be investigating at AHA 2016| Pharma intelligence

The American Heart Association (AHA) Scientific Sessions will be held in New Orleans, LA from 12–16 November 2016.

This year's conference features a number of prominent data presentations, including a highly anticipated session on PCSK9 inhibitors and the long awaited results from Cardiorentis’s TRUE-AHF trial. Details from PCSK9 inhibitor studies will be featured in a late-breaking session on lipid trials, including atherosclerosis imaging from Repatha's (evolocumab; Amgen) GLAGOV trial and extended dosing from PCKS9si (The Medicine's Company, Alnylam). New Phase III heart failure data for ularitide (Cardiorentis) are also highly anticipated. The data were supposed to be presented at the last American College of Cardiology meeting, but there were last-minute issues that the investigators wanted to fully validate. While Xarelto (rivaroxaban; Bayer/Johnson & Johnson) has struggled in the acute coronary syndrome indication, there will be new data on its use in patients undergoing percutaneous coronary intervention (PCI) who have atrial fibrillation, which could prove successful for the drug as it is being compared to vitamin K antagonists. On the device front, investigational device exemption (IDE) study data on HeartMate 3 (St. Jude Medical) versus HeartMate 2 will help determine if changes to the left-ventricular assist device (LVAD) have led to the hoped-for improvements.